Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Differential requirements for Tousled-like kinases 1 and 2 in mammalian development.

Segura-Bayona S, Knobel PA, González-Burón H, Youssef SA, Peña-Blanco A, Coyaud É, López-Rovira T, Rein K, Palenzuela L, Colombelli J, Forrow S, Raught B, Groth A, de Bruin A, Stracker TH.

Cell Death Differ. 2017 Nov;24(11):1872-1885. doi: 10.1038/cdd.2017.108. Epub 2017 Jul 14.

PMID:
28708136
2.

GEMC1 is a critical regulator of multiciliated cell differentiation.

Terré B, Piergiovanni G, Segura-Bayona S, Gil-Gómez G, Youssef SA, Attolini CS, Wilsch-Bräuninger M, Jung C, Rojas AM, Marjanović M, Knobel PA, Palenzuela L, López-Rovira T, Forrow S, Huttner WB, Valverde MA, de Bruin A, Costanzo V, Stracker TH.

EMBO J. 2016 May 2;35(9):942-60. doi: 10.15252/embj.201592821. Epub 2016 Mar 1.

3.

Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel.

Walsh KE, Cutrona SL, Foy S, Baker MA, Forrow S, Shoaibi A, Pawloski PA, Conroy M, Fine AM, Nigrovic LE, Selvam N, Selvan MS, Cooper WO, Andrade S.

Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1205-13. doi: 10.1002/pds.3505. Epub 2013 Sep 5.

4.

Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program.

Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, Ng D, Butler MG, Boudreau D, Forrow S, Goldberg R, Gore J, McManus D, Racoosin JA, Gurwitz JH.

Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):40-54. doi: 10.1002/pds.3310. Epub 2012 Jun 29.

5.

Design for validation of acute myocardial infarction cases in Mini-Sentinel.

Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, Racoosin JA, Goldberg R, Gurwitz JH.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:274-81. doi: 10.1002/pds.2314.

6.

The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.

Forrow S, Campion DM, Herrinton LJ, Nair VP, Robb MA, Wilson M, Platt R.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:12-7. doi: 10.1002/pds.2242.

PMID:
22262588
7.

Hepatic overexpression of a constitutively active form of liver glycogen synthase improves glucose homeostasis.

Ros S, Zafra D, Valles-Ortega J, García-Rocha M, Forrow S, Domínguez J, Calbó J, Guinovart JJ.

J Biol Chem. 2010 Nov 26;285(48):37170-7. doi: 10.1074/jbc.M110.157396. Epub 2010 Sep 14.

8.

The atypical chemokine receptor CCX-CKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses.

Comerford I, Nibbs RJ, Litchfield W, Bunting M, Harata-Lee Y, Haylock-Jacobs S, Forrow S, Korner H, McColl SR.

Blood. 2010 Nov 18;116(20):4130-40. doi: 10.1182/blood-2010-01-264390. Epub 2010 Jun 18.

9.

Chemokine scavenger D6 is expressed by trophoblasts and aids the survival of mouse embryos transferred into allogeneic recipients.

Madigan J, Freeman DJ, Menzies F, Forrow S, Nelson SM, Young A, Sharkey A, Moffett A, Graham GJ, Greer IA, Rot A, Nibbs RJ.

J Immunol. 2010 Mar 15;184(6):3202-12. doi: 10.4049/jimmunol.0902118. Epub 2010 Feb 10.

10.

Tissue selective expression of conditionally-regulated ROCK by gene targeting to a defined locus.

Samuel MS, Munro J, Bryson S, Forrow S, Stevenson D, Olson MF.

Genesis. 2009 Jul;47(7):440-6. doi: 10.1002/dvg.20519.

PMID:
19391117
11.

The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.

Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD, Graham GJ.

J Clin Invest. 2007 Jul;117(7):1884-92.

12.

The effects of a mutant connexin 26 on epidermal differentiation.

Bakirtzis G, Jamieson S, Aasen T, Bryson S, Forrow S, Tetley L, Finbow M, Greenhalgh D, Hodgins M.

Cell Commun Adhes. 2003 Jul-Dec;10(4-6):359-64.

PMID:
14681042
13.

Targeted epidermal expression of mutant Connexin 26(D66H) mimics true Vohwinkel syndrome and provides a model for the pathogenesis of dominant connexin disorders.

Bakirtzis G, Choudhry R, Aasen T, Shore L, Brown K, Bryson S, Forrow S, Tetley L, Finbow M, Greenhalgh D, Hodgins M.

Hum Mol Genet. 2003 Jul 15;12(14):1737-44.

PMID:
12837696
14.

Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.

Wilson SC, Howard PW, Forrow SM, Hartley JA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE.

J Med Chem. 1999 Oct 7;42(20):4028-41.

PMID:
10514273
15.

Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines.

Puvvada MS, Forrow SA, Hartley JA, Stephenson P, Gibson I, Jenkins TC, Thurston DE.

Biochemistry. 1997 Mar 4;36(9):2478-84.

PMID:
9054552
16.

The effect of AT and GC sequence specific minor groove-binding agents on restriction endonuclease activity.

Forrow SM, Lee M, Souhami RL, Hartley JA.

Chem Biol Interact. 1995 May 19;96(2):125-42.

PMID:
7728903
17.

Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents.

Lee M, Rhodes AL, Wyatt MD, Forrow S, Hartley JA.

Anticancer Drug Des. 1993 Jun;8(3):173-92.

PMID:
8517912
19.

In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.

Lee M, Rhodes AL, Wyatt MD, D'Incalci M, Forrow S, Hartley JA.

J Med Chem. 1993 Apr 2;36(7):863-70.

PMID:
8464041
20.

Determination of hydrazine in biofluids by capillary gas chromatography with nitrogen-sensitive or mass spectrometric detection.

Preece NE, Forrow S, Ghatineh S, Langley GJ, Timbrell JA.

J Chromatogr. 1992 Jan 17;573(2):227-34.

PMID:
1601955
21.

Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase.

Ponti M, Forrow SM, Souhami RL, D'Incalci M, Hartley JA.

Nucleic Acids Res. 1991 Jun 11;19(11):2929-33.

22.
23.

Photosensitization of human leukemic cells by anthracenedione antitumor agents.

Hartley JA, Forrow SM, Souhami RL, Reszka K, Lown JW.

Cancer Res. 1990 Mar 15;50(6):1936-40.

Supplemental Content

Loading ...
Support Center